Table 2. Individual patient characteristics and their best tumor responses.
| Patient number | Gender/age (years) | Smoking | Surgery | Histology | Stage | Metastatic site | Agent of combination strategy | Lines of therapy | Best tumor response |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Female/34 | No | No | Squamous cell carcinoma | IVa | Pleura | PD-1 + apatinib/anlotinib | 2 | SD |
| 2 | Female/50 | No | No | Squamous cell carcinoma | IVb | Liver | PD-1 + apatinib | 2 | SD |
| 3 | Female/47 | No | Yes | Type AB thymoma | IVa | Pleura | PD-1 + apatinib | 1 | PR |
| 4 | Female/35 | No | No | Poorly differentiated carcinoma | IVb | Liver, bone | PD-1 + apatinib | 3 | SD |
| 5 | Female/60 | No | No | Poorly differentiated carcinoma | IVb | Pleura, lung | PD-1 + apatinib | 4 | PR |
| 6 | Male/47 | Yes | Yes | Sarcomatoid carcinoma | IVb | Pleura, bone | PD-1 + anlotinib | 2 | SD |
| 7 | Female/49 | No | No | Thymoma | IVb | Bone | PD-1 + apatinib | 3 | SD |
| 8 | Female/53 | No | No | Squamous cell carcinoma | IVb | Lung, liver | PD-1+ lenvatinib | 5 | SD |
| 9 | Male/72 | Yes | No | Squamous cell carcinoma | IVb | Liver | PD-1 + anlotinib | 4 | SD |
| 10 | Female/49 | No | Yes | Squamous cell carcinoma | IVb | Lung, liver, bone | PD-L1 + anlotinib | 4 | PD |
PD-1, programmed death 1; SD, stable response; PR, partial response; PD-L1, programmed death-ligand 1; PD, progressive disease.